AnaptysBio
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 117
- Market Cap
- $1.1B
- Website
- http://www.anaptysbio.com
- Introduction
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
- Conditions
- Palmoplantar Pustulosis
- Interventions
- Drug: PlaceboBiological: Imsidolimab
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- AnaptysBio, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT03633396
- Locations
- 🇺🇸
Riverchase Dermatology and Cosmetic Surgery, Pembroke Pines, Florida, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸T. Joseph Raoof, MD, Inc., Encino, California, United States
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis
- Conditions
- Generalized Pustular Psoriasis
- Interventions
- Biological: Imsidolimab
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- AnaptysBio, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03619902
- Locations
- 🇺🇸
Site 102, Encino, California, United States
🇺🇸Site 105, Largo, Florida, United States
🇺🇸Site 104, Miami, Florida, United States
Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- Conditions
- Chronic Rhinosinusitis
- Interventions
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- AnaptysBio, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT03614923
- Locations
- 🇺🇸
Intermountain Ear Nose Throat Specialist, Draper, Utah, United States
🇺🇸Chesapeake Clinical Research Inc., Baltimore, Maryland, United States
🇺🇸Asthma & Allergy Institute, Little Rock, Arkansas, United States
Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Biological: EtokimabDrug: Placebo
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- AnaptysBio, Inc.
- Target Recruit Count
- 302
- Registration Number
- NCT03533751
- Locations
- 🇺🇸
Ohio State University Clinical Trials Management Office, Columbus, Ohio, United States
🇵🇱Laser Clinic S.C., Szczecin, Poland
🇵🇱Clinical Research Group Sp. z o.o., Warszawa, Poland
Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma
- Conditions
- Eosinophilic Asthma
- Interventions
- Biological: EtokimabDrug: Placebo
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- AnaptysBio, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT03469934
- Locations
- 🇬🇧
Glenfield Hospital, Leicester, Leicestershire, United Kingdom
🇺🇸Allergy & Asthma Center of Southern Oregon, Medford, Oregon, United States
🇬🇧Churchill Hospital, Oxford, Oxfordshire, United Kingdom
Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- AnaptysBio, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02920021
- Locations
- 🇺🇸
Asthma, Inc Clinical Research Center, Seattle, Washington, United States
🇺🇸Stanford Univ. Medical Center, Palo Alto, California, United States